Doctors think theyve discovered another potential coronavirus cure – BGR

The novel coronavirus might not have a cure right now, but its still worth acknowledging the massive research effort that goes into discovering treatments that can limit COVID-19 complications and prevent death. Doctors have observed the positive effects of a garden variety of drugs that are supposed to treat other illnesses, and some of these medicines are included in massive trials around the world. Scientists are also working on over 70 vaccine candidates for COVID-19, with some of them already showing promising results. On top of that, theres plasma from survivors thats rich in antibodies that can help people with weaker immune systems. And doctors think theyve discovered another promising treatment for COVID-19: Stem cells.

You often hear about stem cells and those reports are often miraculous in nature. Stem cells are human cells that have the superpower to transform into almost any cell of the body and they can be used to treat some medical conditions. Stem cells could regenerate lung tissue, fight inflammation, and help severe COVID-19 patients breathe on their own again. The problem with this line of thinking is that we just dont know.

Doctors at Mount Sinai treated 12 patients with stem cell therapy, and 10 of them came off their ventilators soon after, CBSNews reports. The doctors themselves have no idea what helped the patients improve, and cant definitively say that its the stem cells that saved their patients.

What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better, Dr. Karen Osman told CBS. The doctor made it clear that they cant claim the stem cell treatments are what saved the patients. We dont know, she said. And we would never dare to claim that it was related to the cells.

The doctor explained that only a randomized controlled trial would be able to tell them whether the stem cells can help with the recovery of COVID-19 patients. Thankfully, one such study is about to get underway. Mesoblast will trial stem cell treatments on 300 patients suffering from severe lung inflammation.

Osman and her team believe that stem cells extracted from bone marrow could suppress the inflammation in COVID-19 patients, and thats why they attempted the therapy. One such patient was 60-year-old Luis Naranjo who spent 14 days unconscious on a ventilator and lost 25 pounds while hospitalized of COVID-19. Naranjo has completely recovered following stem cell therapy, and hes at home working on regaining his strength.

If it works, stem therapy would still not be a miracle treatment, Osman says. The miracle treatment will be a vaccine. While we wait for any sort of efficient COVID-19 treatment, heres a simple explainer for stem cells:

Image Source: Darko Vojinovic/AP/Shutterstock

Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.

Read more:
Doctors think theyve discovered another potential coronavirus cure - BGR

Assessing the Fallout From the Coronavirus Pandemic Value of Canine Stem Cell Therapy Market Predicted to Surpass US$ by the of 20512019-2019 -…

Given the debilitating impact of COVID-19 (Coronavirus) on the Canine Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Canine Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Canine Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Canine Stem Cell Therapy market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Canine Stem Cell Therapy market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Canine Stem Cell Therapy market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

Regional Overview

Our team of analysts at PMR, trace the major developments within the Canine Stem Cell Therapy landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Canine Stem Cell Therapy market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

Key Takeways Enclosed in the Report:

Queries Related to the Canine Stem Cell Therapy Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Why Opt for Persistence Market Research?

See original here:
Assessing the Fallout From the Coronavirus Pandemic Value of Canine Stem Cell Therapy Market Predicted to Surpass US$ by the of 20512019-2019 -...

Stem Cell Cartilage Regeneration Market 2020: Production, Sales, Supply, Demand, Analysis and Forecast To 2026 – Cole of Duty

The Stem Cell Cartilage Regeneration market demand is anticipated to flourish during the forecast period 2020-2027. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Stem Cell Cartilage Regeneration market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth and future. An in-depth analysis of the major companies operating in the market is also mentioned in this research report.

The global Stem Cell Cartilage Regeneration market is segmented on the basis of type and application. It also provides market size and forecast estimates from the year 2020 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and South America (SAM). The Stem Cell Cartilage Regeneration market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of top countries globally along with the current trend and opportunities prevailing in the region.

Receive Sample of Stem Cell Cartilage Regeneration Research Industry @ https://www.coherentmarketinsights.com/insight/request-sample/2448

A thorough examination of the Stem Cell Cartilage Regeneration market includes each and every aspect, which begins with knowing the market, speaking with clients, and evaluating the complete data of the global market. For more clarification, the global market is segmented on the basis of the manufacture of the kind of products, and their applications. The report also delivers information as per the regions based on the geographical classification of the global Stem Cell Cartilage Regeneration market. The dynamic foundation of the global market is based on the calculation of product supply in different markets, their revenues, capability, and a chain of production.

Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information.

Furthermore, this study will help our clients solve the following issues:

All in all, the Stem Cell Cartilage Regeneration market research study elucidates a detailed evaluation of this business and projects this industry to register a commendable growth rate in the forthcoming years. The Stem Cell Cartilage Regeneration market analysis report also delivers important insights with respect to aspects such as the volume of sales, valuation forecast, market size, and the market competition trends as well as the market concentration rate.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2448

Have a look on Key Questions Answered in this Report:

Finally, this business guide will be helpful for both established and new players to sustain in the competitive Stem Cell Cartilage Regeneration market world as it mentions the key geographies, market landscapes alongside the product price, revenue, volume, production, supply, demand, and market growth rate & gives the maximum possible profit for your company.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:[emailprotected]

U.S. Office:Name: Mr. ShahCoherent Market Insights 1001 4th Ave,# 3200 Seattle, WA 98154, U.S.US : +1-206-701-6702UK : +44-020-8133-4027JAPAN : +050-5539-1737LinkedIn | Twitter | Infographics

Know More About Similar Reports: http://bit.ly/Rajkumar123

Here is the original post:
Stem Cell Cartilage Regeneration Market 2020: Production, Sales, Supply, Demand, Analysis and Forecast To 2026 - Cole of Duty

Covid has proved we havent spent enough on life science research. Time to make up now – ThePrint

Text Size:A- A+

Indias life sciences sector, including pharmaceuticals, diagnostics, medical devices, clinical research, and digital health, has been at the forefront of our battle against the coronavirus pandemic. Domestic pharma companies are developing drugsandvaccines.Some have alsodeveloped testsand are rolling out testingservices. Indias hydroxychloroquine is being exported around theworldand is in great demandto aid the treatment of Covid patients.

Meanwhile, the Aarogya Setu contact tracing app has alreadyseenmore than 7.5 croredownloads.

We must now further strengthen the life sciences sector to meet the demands of the future. This will require a multi-dimensional approach.

Also read: To achieve herd immunity, vaccine and a data-driven approach needed: WHO chief scientist

First. There must beclose industry-government collaboration to develop and fine-tune regulations to promote fast growthfor the sector.

Second. We must ensure that we rapidly build up our life sciences workforce so that we can have enough talented people available for both the health care and the life sciencessectors.

Third. We should consider whether we are providing enough financial support for sectoral growth.

And, finally, we must leverage the fast-emerging IndianSuperCloudto connect all our life sciences activity.

Some of our life sciences enterprises are nowworld leaderssuch as Cipla, Aurobindo, Lupin, and DRL.Some 50per centof the worlds vaccines are produced in India. We also produce 20per centof the worlds generic medicines. The pharma industry alone generates close to $20 billion inannual exports.

Our skilled doctors, nurses, and other life sciences professionals are leading major research programmes in India and around the world. The coronavirus pandemic has proven to all of us that we have not been spending enough on life sciences and health care.

Resources and spending willneed togrow dramatically to protect the worlds population. Life sciences companies should now work closely with our various regulators and policy-makers throughempowered working groups to driveupinvestment, growth, and jobs.

Also read: Made-in-India Covid-19 vaccine could be ready in a year, says Biocons Kiran Mazumdar-Shaw

Life sciencesisa tightly regulated sector. In India, we have several regulators across multiple ministries that have oversight over the sector.

The National Pharmaceutical Pricing Authority (NPPA) sets prices for bulk drugs and formulations and is within the ministry of chemicals and fertilisers. The ministry of health and family welfare manages the safety, efficacy, and quality of drugs and medical devices through the Central Drugs Standard Control Organisation. In the same ministry, the National Health Portal of India is formulating Electronic Health Record (EHR) standards, which will also be governed by the Personal Data Protection bill, being handled by the ministry of electronics and information technology.

Alllife sciences research is conducted under the guidelines established by the Indian Council of Medical Research and the Ministry of Science & Technology. The Ayush Ministry and Niti Aayog also play an important role in the life sciences sector.Although healthis a state subject and each state can develop policies to support the sector,it is important thatall these regulators anddecision-makers,both at the centre and the state level, working with industry,developcoordinatedresponse forsectoral growth.

Also read: Covid-19 response is a chance for companies to place planet over profits

Along with deep collaboration between industry and government at all levels, we must also build up our life sciences workforce. Today we have 535 medical colleges in India graduating about 79,000 students every year. It is estimated that we currentlyhave 300,000 annualnursing seatsavailable. In addition, there are lakhs of biology, biotechnology, and chemistry students graduating every yearwhocan be employed in the life sciences sector.

That said, we still have only 0.7 doctors per 1,000 people against the minimumWorld Health Organizationsstandard of 1 per 1000 people. For nurses, we are at 1.7 when we should be at 2.5. In addition, we need to provide our educational institutions withsignificantly higherresearch funding so that we can get more young scientists and researchersto work towards developingcutting-edgesolutionsin drugs,devices, andtherapiessegments.

Also read: Critical drugs supply must not be disrupted, EU envoy says as India bans & resumes exports

Government funding worththousands of crores of rupees is required to drive this researchculture in India. An expert panel could be constituted to select 10-15 researchareassuch as genomics, computational biology, virology, epidemiology, neuroscience, stem cell research, etc.

Multi-year research grants could then be provided to top scientists (in India or from ourcommunity abroad) to pursue their research and train graduate students. Research productivity could then be judged on objective global metrics (high-quality citations, placement of graduate students in top institutions, and so on) to ensure accountability and quality.

We also need to back new life sciences enterprises with venture capital financing. The government has established a Rs 10,000 croreFund-of-Fundsto support venture capital funds. It might be possible to allocate a significant fraction of this money solely to life sciences funds, so that they can provide the necessary financing and support to life sciences startups. This will require that SIDBI have the necessary expertise toidentifyand nurture life sciences funds.

Also read: US drug authority warns Americans not to pop hydroxychloroquine pills without prescription

Finally, Indias fast-emerging SuperCloud can play an important role in the development of the life sciences sector. With high-speed 5G networks and local data centres, telemedicine and remote diagnostics will become fully feasible.

Theprovisions of thenew Personal Data Protection bill will make it possible to develop a secureelectronic health record (EHR)for every individual so that their necessary healthcare eligibility, data, and payments/insurance are available as required. Large local data lakes will enable AI and computational biology to develop therapies targeted for the Indian genome.

Pandemics will come and go,but ournon-communicable disease burden will continue to rise. Around the world, there is a looming shortage of skilled medical professionals and researchers. New, low-cost therapies are in high demand. The Indian life sciences sector can take advantageof these circumstancesto not only protect our health, but also become a growth engine for Indias economy.

Jayant Sinha is the Chairman of the Standing Committee on Finance in Parliament and a Lok Sabha MP from Hazaribagh, Jharkhand. These are his personal views.

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

See more here:
Covid has proved we havent spent enough on life science research. Time to make up now - ThePrint

COVID-19: Potential impact on Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2060 2018 2026 – Latest…

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Amniotic Fluid Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Amniotic Fluid Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Amniotic Fluid Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

The Amniotic Fluid Stem Cell Therapy market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Amniotic Fluid Stem Cell Therapy market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

What pointers are covered in the Amniotic Fluid Stem Cell Therapy market research study?

The Amniotic Fluid Stem Cell Therapy market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Amniotic Fluid Stem Cell Therapy market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Amniotic Fluid Stem Cell Therapy market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Amniotic Fluid Stem Cell Therapy market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Amniotic Fluid Stem Cell Therapy market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Amniotic Fluid Stem Cell Therapy market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

Some of the Major Highlights of TOC covers:

Originally posted here:
COVID-19: Potential impact on Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2060 2018 2026 - Latest...

Mogrify strikes deal with US biopharma Sangamo Therapeutics – Cambridge Independent

Cell conversion specialist Mogrify has announced a collaboration and licence agreement with US genomic medicine company Sangamo Therapeutics.

Under the deal, Brisbane-based Sangamo has an exclusive licence to develop allogeneic cell therapies from Mogrifys proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).

Dr Darrin Disley, CEO of Cambridge Science Park-based Mogrify, said: Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy.

The combination of Mogrifys proprietary systematic cell conversion technology and Sangamos regulatory T cell platform and proprietary ZFP (zinc finger protein) platform is a natural fit. Sangamo is at the forefront of the development of a world-class engineered ZFP genome editing platform and we are very happy to be partnering with such an innovative company.

Mogrify will receive an upfront payment and is eligible for additional payments related to development and regulatory milestones, and product sales.

Jason Fontenot, SVP, head of cell therapy at Sangamo, said: This licence agreement provides Sangamo with access to Mogrifys cell conversion technology, which will diversify our options as we develop off-the-shelf allogeneic CAR-Treg (chimeric antigen receptor regulatory T cell) cell therapies.

We expect this collaboration to accelerate our development of scalable and accessible CAR-Treg cell therapies, so that we can potentially deliver treatments to patients with inflammatory and autoimmune diseases more rapidly.

Mogrifys technology enables the transformation of any human cell type into any other human cell type.

It uses transcription factors or small molecules identified using proprietary big data technologies.

iPSCs and ESCs provide an evergreen starting material for the generation of Tregs. They enable more complex engineering and greater manufacturing scalability.

This could make the resulting therapies more cost-effective and therefore accessible to more patients.

Mogrify will discover and optimise the cell conversion technology from iPSCs or ESCs to regulatory T cells under the agreement, while Sangamo will be granted exclusive rights to use Mogrifys technology to create Tregs from iPSCs or ESCs.

Sangamo expects to use its ZFP gene-engineering technology and therapeutic development capabilities to transform these Tregs into novel off-the-shelf allogeneic CAR-Treg cell therapy candidates.

It aims to take them from clinical development through to registration for the treatment of inflammatory and autoimmune diseases.

Mogrify won the One to Watch award at the 2019 Cambridge Independent Science and Technology Awards.

Read more

Inivata launches RaDaR test to identify residual disease and relapse in cancer patients

Reversing osteoarthritis: Mogrify secures $1.1m from SBRI Healthcare to assess cartilage regeneration therapy

Mogrify cell therapy technology attracts further $16m funding

Darrin Disley returns to lead Mogrifys new cell revolution

Watch the highlights and see the pictures from the Cambridge Independent Science and Technology Awards 2019

See the rest here:
Mogrify strikes deal with US biopharma Sangamo Therapeutics - Cambridge Independent

How could Covid-19 and the body’s immune response affect the brain? – MIT News

To get ahead of the possible long-term neurological problems from infection, multiple labs in The Picower Institute for Learning and Memory at MIT have begun pursuing research to determine whether and how it affects the brain, either directly or via the bodys heightened immune response. If it indeed does, that would be consistent with a history of reports that infections and immune system activity elsewhere in the body may have long-term impacts on mental health.

While some scientists, for instance, suspect a role for infectious diseases in neurodegenerative disorders such as Parkinsons disease or dementias, Picower Institute Member Gloria Choi and Harvard University immunologist Jun Huh have meticulously traced the pathway by which infection in a pregnant mother can lead to autism-like symptoms in her child and how, counterintuitively, infection in people with some autism spectrum disorders can temporarily mitigate behavioral symptoms. With deep expertise in neuro-immune interactions, as well as in the neural systems underlying the sense of smell, which is reported to be lost in some Covid-19 patients, Choi is planning several collaborative coronavirus studies.

With these various suspected neurological symptoms, if we can determine the underlying mechanisms by which the immune system affects the nervous system upon the infection with SARS-CoV-2 or related viruses, then the next time the pandemic comes we can be prepared to intervene, says Choi, Samuel A. Goldblith Career Development Assistant Professor of Applied Biology in the Department of Brain and Cognitive Sciences.

Like Choi, Picower Professor Li-Huei Tsai is also planning studies of the neurological impact of Covid-19. Tsais studies of Alzheimers disease include investigation of the blood-brain barrier, which tightly gates what goes into and out of the brain through the circulatory system. Technologies that her lab is developing with collaborators including MIT Institute Professor Robert Langer put the team in a unique position to assess whether and how coronavirus infection might overrun or evade that safeguard.

It is critical to know how the coronavirus might affect the brain, Tsai says. We are eager to bring our technology to bear on that question.

Neuro-immune interactions

Choi is considering three lines of coronavirus research. Together with Picower Institute colleagues Newton Professor Mriganka Sur and Assistant Professor Kwanghun Chung, she hopes to tackle the question of anosmia, the loss of smell. Choi has studied the olfactory system in mice since her graduate and postdoc days. Moreover, a key finding of her neuroimmunology research is that because neurons express receptors for some of the signaling molecules, called cytokines, emitted by immune system cells, those interactions can directly affect neural development and activity. Working in mouse models, the team plans to ask whether such an impact, amid the immune systems heightened response to Covid-19, is occurring in the olfactory system.

Based on her and Huhs studies of how maternal infection leads to autism-like symptoms in their offspring, they are concerned about two other aspects of coronavirus infection. One builds on the finding that the risk of offspring developing neurological problems depended strongly on the composition of the pregnant mothers gut microbiome, the populations of bacteria that everyone harbors within their body. Given the wide range of outcomes seen among coronavirus patients, Choi and Huh wonder whether microbiome composition may play a role in addition to factors such as age or underlying health conditions. If that turns out to be the case, then tweaking the microbiome, perhaps with diet or probiotics, could improve outcomes. Working with colleagues in Korea and Japan, they are embarking on studies that will correlate microbiome composition in patients with their coronavirus outcomes.

Over the longer term, Choi and Huh also hope to study whether Covid-19 infection among pregnant mothers presents an elevated risk of their offspring developing neurodevelopmental disorders like autism. In their research in mice, they have showed that given a particular maternal microbiome composition, immune cells in pregnant mice expressed elevated levels of the cytokine IL-17a. The molecule directly influenced fetal brain development, causing neural circuits governing autism-like behavioral symptoms to develop improperly. The pair aim to assess whether that could happen with coronavirus.

Covid-19 access to the brain

A major question is whether and how the SARS-CoV-2 virus can reach the central nervous system. Tsais lab may be able to find out using an advanced laboratory model of the blood-brain barrier (BBB), whose development has been led by postdoc Joel Blanchard. In a study in press, he has shown that the model made of human astrocytes, brain endothelial cells, and pericytes cultured from induced pluripotent stem cells closely mirrors properties of the natural BBB, such as permeability. In collaboration with Langer, the team is integrating the model with induced pluripotent stem cell-derived cultures of neurons and other crucial brain support cells, like microglia and oligodendrocytes, on a chip (called a miBrain chip) to provide a sophisticated and integrated testbed of brain cell and cerebral vascular interaction.

With the miBrain chip platform Tsais lab plans several experiments to better understand how the virus may put the brain at risk. In one, they can culture miBrain chips from a variety of individuals to see whether the virus is able to permeate the BBB equally or differently in those personalized models. They can also test another means of viral entry into the brain whether the bodys immune system response (a so-called cytokine storm) increases the BBBs permeability by using blood serum from Covid-19 patients in the miBrainChip model.

Yet another way the virus might spread in the nervous system is from neuron to neuron via their connections called synapses. With cultures of thousands of neurons, the miBrain chip platform could help them determine whether thats the case, and whether specific kinds of neurons are more susceptible to becoming such conduits.

Finally, there may be genetic differences that increase susceptibility to viral entry to the brain. Using technologies like CRISPR/Cas9, the team can engineer such candidate risk genes into the BBBs to test whether permeability varies. In their Alzheimers disease research, for example, they study whether variations in a gene called ApoE causes different degrees of amyloid proteins plaque buildup in the BBB model.

The potential interactions among the virus, the microbiome, the immune system, and the central nervous system are likely to be highly complex, but with the expertise, the tools, and strong collaborations, Picower Institute researchers see ways to help illuminate the possible neurological effects of coronavirus infection.

Read more here:
How could Covid-19 and the body's immune response affect the brain? - MIT News

Induced Pluripotent Stem Cells Market Overview, Top Companies, Region, Application and Global Forecast by 2026 – Latest Herald

Reprocell

Global Induced Pluripotent Stem Cells Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=219183&utm_source=LHN&utm_medium=888

Induced Pluripotent Stem Cells Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Induced Pluripotent Stem Cells industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Induced Pluripotent Stem Cells industry.

-> Furthermore, we will help you to identify any crucial trends to predict Induced Pluripotent Stem Cells market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Induced Pluripotent Stem Cells market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=219183&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Induced Pluripotent Stem Cells market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Induced Pluripotent Stem Cells market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Induced Pluripotent Stem Cells Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Induced Pluripotent Stem Cells Market Size, Induced Pluripotent Stem Cells Market Growth, Induced Pluripotent Stem Cells Market Forecast, Induced Pluripotent Stem Cells Market Analysis

Our Trending Reports

Epoxy Adhesives Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Explosion Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Induced Pluripotent Stem Cells Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

FDA Expediting Accelerated Development of Novel Therapies for COVID-19 – Yahoo Finance

Financialnewsmedia.com News Commentary

PALM BEACH, Florida, April 28, 2020 /PRNewswire/ --The U.S. Federal government is working closely with companies and researchers to find treatments and vaccines to overcome the global health crisis. The FDA has been cutting red tape and has launched new programs that relax certain time consuming regulations while still assuring the efficacy and safety of the treatments. The FDA recently issued an update describing its most recent programs. The update stated that, as part of the administration's: " all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency's disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus. Active healthcare stocks in news today include: Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), Mesoblast Limited (NASDAQ: MESO), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences, Inc. (NASDAQ: GILD), Aytu BioScience, Inc. (NASDAQ: AYTU).

"The FDA is announcing a new, comprehensive public-private approach to bring coronavirus treatments to market as fast as possible," said HHS Secretary Alex Azar. "As part of this new program, the FDA is cutting red tape, redeploying staff and working day and night to review requests from companies, scientists and doctors who are working toward therapies. We are grateful to the men and women of the FDA who have been working in concert with industry and other parts of HHS to support potential coronavirus treatments for weeks now. Each day, President Trump's all-of-America approach is making progress and providing new hope in our fight against the coronavirus."

There are a large number of companies and researchers developing and evaluating COVID-19 related therapies. Given the urgent nature of the pandemic, under the FDA's accelerator program, staff from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research are providing regulatory advice, guidance and technical assistance as quickly as possible. As part of this work, the FDA is triaging requests from developers and scientists seeking to develop new drug and biologic therapies, getting the relevant FDA staff in touch with them and providing rapid, interactive input to get studies underway quickly.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)BREAKING NEWS - Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 - Citius Pharmaceuticals ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, this week announcedthat it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

The cells, called NoveCite Cells or NC-MSCs, are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. NC-MSCs are mesenchymal stem cells derived from a single donor's fibroblasts that have been dedifferentiated into an induced pluripotent stem cell (iPSC) master cell bank, thereby avoiding the need to source additional donor cells. The iPSCs are then further differentiated into a mesenchymal stem cell (MSC) therapy. Citius and Novellus plan to develop NC-MSCs for the treatment of ARDS, and last month the companies signed an exclusive option agreement.

The Company plans a multi-center randomized placebo-controlled dose-finding study followed by an expansion phase to assess the safety, tolerability, and efficacy of NC-MSCs in patients with moderate to severe ARDS due to COVID-19. The proposed trial, a Phase 1b/2 clinical trial, is titled "A Randomized Placebo-Controlled Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19)," or "MARCO". The primary objectives of this study are to evaluate the safety and efficacy of NoveCite cells as a treatment for subjects with moderate-to-severe ARDS due to COVID-19 and to identify therapeutic doses.

Story continues

"MSCs have an established track-record of clinical safety, and have shown promise in the treatment of inflammatory lung disease," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus, Inc. "Our research has shown that the NoveCite cells, being derived from mRNA-reprogrammed iPSCs, secrete higher levels of immunomodulatory proteins than donor-derived MSCs, and have unique manufacturing advantages."

"We believe we have the key elements in place from a clinical design and manufacturing point of view to evaluate this novel cell therapy approach to deal with the current pandemic," said Myron Holubiak, Chief Executive Officer of Citius. "ARDS is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80% of the deaths in ventilated patients. There is no proven or FDA-approved treatment for it, other than oxygen therapy, including use of mechanical ventilation, and fluid management. Literature from previous investigational studies with MSCs in the treatment of lung injuries support the idea that MSCs could prove effective in treating COVID-19-related ARDS. We look forward to our FDA discussions and are excited to be at the cusp of what could be a novel and effective therapy for ARDS." Read this full release at: https://ir.citiuspharma.com/press-releases/detail/96/citius-announces-pre-ind-submission-to-fda-under-the

In other healthcare news of note:

Mesoblast Limited (NASDAQ: MESO) recently announced 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days. 75% (9/12) have successfully come off ventilator support at a median of 10 days. At this time, seven have been discharged from the hospital. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at New York City's Mt Sinai hospital.

In contrast, only 9% (38/445) of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated with standard of care during March/April 2020.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced this week that first quarter 2020 financial results will be released after the market close on May 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's ongoing vaccine developments for COVID-19. A live and archived version of the audio presentation will be available online at http://ir.inovio.com/investors/events/default.aspx. This is a listen-only event but will include a live Q&A with analysts. Telephone replay will be available approximately one hour after the call at 877-344-7529 (US toll free) or 412-317-0088 (international toll) using replay access code 10143530.

Gilead Sciences, Inc. (NASDAQ: GILD) Kite, a Gilead Company, and oNKo-innate recently announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.

Current cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity, including checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play a critical surveillance and effector role in the immune system. NK cells and T cells each have the potential to attack cancer cells, but have different mechanisms for tumor cell killing. Thus, appropriately activated and targeted NK cells may represent a differentiated approach that would be potentially complementary and synergistic with T cell mediated anti-tumor strategies.

Aytu BioScience, Inc. (NASDAQ: AYTU) recently announced that it has signed an agreement with Sterling Medical Devices ("Sterling") to finalize the development of Healight, a novel endotracheal catheter, as a potential treatment for coronavirus.

The company announced last week that it licensed exclusive worldwide rights to the Healight technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. The patent-pending Healight Platform has been in development since 2016 by the Medically Associated Science and Technology (MAST) team at Cedars-Sinai. Following their pre-clinical findings that Healight may be a safe and effective antiviral and antibacterial treatment, the team engaged Sterling to rapidly develop a novel endotracheal device to help combat coronavirus.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated forty five hundred dollars for news coverage of the current press releases issued by Citius Pharmaceuticals, Inc. by a non affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:editor@financialnewsmedia.com,+1(561)325-8757

View original content:http://www.prnewswire.com/news-releases/fda-expediting-accelerated-development-of-novel-therapies-for-covid-19-301047923.html

SOURCE Financialnewsmedia.com

Visit link:
FDA Expediting Accelerated Development of Novel Therapies for COVID-19 - Yahoo Finance

GLOBAL TOOTH REGENERATION MARKET: INDUSTRY ANALYSIS AND FORECAST (2020-2027) – MR Invasion

Global Tooth Regeneration Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 6.5% during a forecast period 2020-2027.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/55424/

Global Tooth Regeneration Market

Market Dynamics

The Research Report gives a comprehensive account of the drivers and restraints in the tooth regeneration.Somatic stem cells are composed and reprogrammed to induced pluripotent stem cells which can be placed in the dental lamina directly or placed in an absorbable biopolymer in the shape of the new tooth, which is a main source of the novel bioengineered teeth. Tooth replacement therapy is pondered to be a greatly attractive concept for the next generation bioengineered organ replacement. The global tooth regeneration market is mainly compelled by the high occurrence of dental problems with the new research and development activities. According to WHO, the Global Burden of Disease Study 2017 estimated that oral diseases affect close to 3.5 billion people worldwide, with caries of permanent teeth being the most common condition. Globally, it is likely that 2.3 billion people suffer from caries of permanent teeth and more than 530 million children suffer from caries of primary teeth. Additionally, positive refund policies for instance coverage of Medicaid insurance for dental loss treatment and emergence of new technologies like laser tooth generation techniques are projected to enhance the global tooth generation market throughout the estimated period.

Different researches are carried out by several academies and corporations to understand the possibility of stem cell-based regenerative medicines tooth regeneration. Though stem cell is the protuberant technology in research for tooth regeneration, several organizations are also leveraging laser, drug, and gel as mediums to regenerate teeth. For example, the Wyss Institute at Harvard University is engaged in research related to tooth regeneration using lasers. Tooth generation using stem cells is now under research through the globe. There are some key stem cells on which research are carried out such as stem cells from human exfoliated deciduous teeth (SHEDs), dental pulp stem cells, dental follicle progenitor cells (DFPCs), periodontal ligament stem cells (PDLSCs), and stem cells from apical papilla (SCAPs).A 2009 nationwide survey by the Nova South-eastern University in the U.S. publicized that around 96% of dentists expect stem cell regeneration to lead the future of the dentistry industry.However, occurrence rates are growing in low and middle-income countries. Though, some factors like the preference for endodontic treatment over tooth regeneration products in key dental surgeries and local inflammatory activity, which results in chronic complications to dental replacements, is anticipated to hamper the market throughout the forecast period.

Global Tooth Regeneration Market Segment analysis

Based on population demographics, the geriatric segment is expected to grow at a CAGR of XX% during the forecast period. According to NIH, the geriatric population has an average 18.9 remaining teeth. About 23% of the geriatric population has no teeth, making a positive market situation for manufacturing companies. The above 18 million dental procedures are anticipated to be carried out amongst the geriatric population between 2019 and 2027. Commercialization of tooth regeneration is expected to create lucrative market opportunities for industry players.Based on Type, the dentin segment accounted for a projecting share of the global tooth regeneration market in 2019, owing to the growing occurrence of dental surgery and the uprising demand for tooth regeneration in cosmetic surgery, particularly from developing economies like India, China, and Brazil.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/55424/

Global Tooth Regeneration Market Regional analysis

The Asia Pacific is projected to dominate the global tooth regeneration market throughout the forecast period. Tooth regeneration addressable market is likely to be highest in the Asia Pacific, with China and India located as the major growth engines. The occurrence of tooth regeneration is projected to capture this market. Also, the number of dental procedures is anticipated to grow at the highest CAGR of ~10.8% in the Asia Pacific between 2019 and 2027. Besides, the growing incidence of dental cavities & periodontics, particularly in emerging countries like China and India has led to the rising demand for orthopedic & dental surgery.North America and Europe are estimated to collectively account for the major share of global procedures during the forecast period.

Key Developments

In June 2018, Datum Dental Ltd., the prominent provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced clearances for OSSIX Bone with Health Canada and CE Mark approval in Europe. OSSIX Bone received FDA clearance in July 2017 and was launched commercially in the USA. In April 2018, Datum Dental, the leading provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced the expansion of its global distribution network. In the USA, Dentsply Sirona Implants is now promoting the full OSSIX line.

The objective of the report is to present a comprehensive analysis of the Global Tooth Regeneration Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Tooth Regeneration Market dynamics, structure by analysing the market segments and projects the Global Tooth Regeneration Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Tooth Regeneration Market make the report investors guide.Scope of the Global Tooth Regeneration Market

Global Tooth Regeneration Market, By Type

Dentin Dental Pulp Tooth EnamelGlobal Tooth Regeneration Market, By Applications

Hospitals Dental Clinics OthersGlobal Tooth Regeneration Market, By Population Demographics

Geriatric Middle-aged Adults OthersGlobal Tooth Regeneration Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Tooth Regeneration Market

Unilever Straumann Dentsply Sirona 3M Zimmer Biomet Ocata Therapeutics Integra LifeSciences Datum Dental CryoLife BioMimetic Therapeutic Cook Medical

MAJOR TOC OF THE REPORT

Chapter One: Tooth Regeneration Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Tooth Regeneration Market Competition, by Players

Chapter Four: Global Tooth Regeneration Market Size by Regions

Chapter Five: North America Tooth Regeneration Revenue by Countries

Chapter Six: Europe Tooth Regeneration Revenue by Countries

Chapter Seven: Asia-Pacific Tooth Regeneration Revenue by Countries

Chapter Eight: South America Tooth Regeneration Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Tooth Regeneration by Countries

Chapter Ten: Global Tooth Regeneration Market Segment by Type

Chapter Eleven: Global Tooth Regeneration Market Segment by Application

Chapter Twelve: Global Tooth Regeneration Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Tooth Regeneration Market Report at:https://www.maximizemarketresearch.com/market-report/global-tooth-regeneration-market/55424/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See the rest here:
GLOBAL TOOTH REGENERATION MARKET: INDUSTRY ANALYSIS AND FORECAST (2020-2027) - MR Invasion